Lazard Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
Lazard Asset Management's ADPT Position: Q3 2026 in Review
Lazard Asset Management reduced its Adaptive Biotechnologies (ADPT) stake by 25% in Q3 2026, selling an estimated $168K and leaving 20,627 shares worth $596K. The position accounts for ﹤0.01% of the portfolio, ranked #1364.
Lazard Asset Management first reported a position in ADPT in Q4 2019 and has held it in 26 quarters since. The position peaked at $46.6M in Q2 2021. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.
- Lazard Asset Management held 20,627 shares of Adaptive Biotechnologies worth $596K as of Q3 2026.
- Lazard Asset Management sold 6,823 Adaptive Biotechnologies shares in Q3 2026, an estimated $168K.
- Adaptive Biotechnologies made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1364 holding.
- Lazard Asset Management first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 26 quarters since.
- Lazard Asset Management's Adaptive Biotechnologies position peaked at $46.6M in Q2 2021.
- 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.